Database : MEDLINE
Search on : Hyperlipidemias [Words]
References found : 25489 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2549 go to page                         

  1 / 25489 MEDLINE  
              next record last record
select
to print
Photocopy
Clinical Trials Registry
Clinical Trials Registry
Full text

[PMID]: 29340676
[Au] Autor:Salminen P; Helmiö M; Ovaska J; Juuti A; Leivonen M; Peromaa-Haavisto P; Hurme S; Soinio M; Nuutila P; Victorzon M
[Ad] Address:Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland.
[Ti] Title:Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial.
[So] Source:JAMA;319(3):241-254, 2018 01 16.
[Is] ISSN:1538-3598
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Importance: Laparoscopic sleeve gastrectomy for treatment of morbid obesity has increased substantially despite the lack of long-term results compared with laparoscopic Roux-en-Y gastric bypass. Objective: To determine whether laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass are equivalent for weight loss at 5 years in patients with morbid obesity. Design, Setting, and Participants: The Sleeve vs Bypass (SLEEVEPASS) multicenter, multisurgeon, open-label, randomized clinical equivalence trial was conducted from March 2008 until June 2010 in Finland. The trial enrolled 240 morbidly obese patients aged 18 to 60 years, who were randomly assigned to sleeve gastrectomy or gastric bypass with a 5-year follow-up period (last follow-up, October 14, 2015). Interventions: Laparoscopic sleeve gastrectomy (n = 121) or laparoscopic Roux-en-Y gastric bypass (n = 119). Main Outcomes and Measures: The primary end point was weight loss evaluated by percentage excess weight loss. Prespecified equivalence margins for the clinical significance of weight loss differences between gastric bypass and sleeve gastrectomy were -9% to +9% excess weight loss. Secondary end points included resolution of comorbidities, improvement of quality of life (QOL), all adverse events (overall morbidity), and mortality. Results: Among 240 patients randomized (mean age, 48 [SD, 9] years; mean baseline body mass index, 45.9, [SD, 6.0]; 69.6% women), 80.4% completed the 5-year follow-up. At baseline, 42.1% had type 2 diabetes, 34.6% dyslipidemia, and 70.8% hypertension. The estimated mean percentage excess weight loss at 5 years was 49% (95% CI, 45%-52%) after sleeve gastrectomy and 57% (95% CI, 53%-61%) after gastric bypass (difference, 8.2 percentage units [95% CI, 3.2%-13.2%], higher in the gastric bypass group) and did not meet criteria for equivalence. Complete or partial remission of type 2 diabetes was seen in 37% (n = 15/41) after sleeve gastrectomy and in 45% (n = 18/40) after gastric bypass (P > .99). Medication for dyslipidemia was discontinued in 47% (n = 14/30) after sleeve gastrectomy and 60% (n = 24/40) after gastric bypass (P = .15) and for hypertension in 29% (n = 20/68) and 51% (n = 37/73) (P = .02), respectively. There was no statistically significant difference in QOL between groups (P = .85) and no treatment-related mortality. At 5 years the overall morbidity rate was 19% (n = 23) for sleeve gastrectomy and 26% (n = 31) for gastric bypass (P = .19). Conclusions and Relevance: Among patients with morbid obesity, use of laparoscopic sleeve gastrectomy compared with use of laparoscopic Roux-en-Y gastric bypass did not meet criteria for equivalence in terms of percentage excess weight loss at 5 years. Although gastric bypass compared with sleeve gastrectomy was associated with greater percentage excess weight loss at 5 years, the difference was not statistically significant, based on the prespecified equivalence margins. Trial Registration: clinicaltrials.gov Identifier: NCT00793143.
[Mh] MeSH terms primary: Gastrectomy
Gastric Bypass
Laparoscopy
Obesity, Morbid/surgery
Weight Loss
[Mh] MeSH terms secundary: Adolescent
Adult
Diabetes Mellitus, Type 2/complications
Female
Follow-Up Studies
Gastrectomy/adverse effects
Gastrectomy/methods
Gastric Bypass/adverse effects
Gastric Bypass/methods
Humans
Hyperlipidemias/complications
Hypertension/complications
Male
Middle Aged
Obesity, Morbid/complications
Obesity, Morbid/physiopathology
Postoperative Complications
Quality of Life
Treatment Outcome
Young Adult
[Pt] Publication type:COMPARATIVE STUDY; EQUIVALENCE TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Em] Entry month:1801
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180118
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.20313

  2 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 29267671
[Au] Autor:Lutfioglu M; Aydogdu A; Atabay VE; Sakallioglu EE; Avci B
[Ad] Address:Ondokuz Mayis University Faculty of Dentistry, Department of Periodontology, Samsun, Turkey.
[Ti] Title:Gingival crevicular fluid oxidative stress level in patients with periodontal disease and hyperlipidemia.
[So] Source:Braz Oral Res;31:e110, 2017 Dec 18.
[Is] ISSN:1807-3107
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:This study aimed to assess the impact of hyperlipidemia on healthy and diseased periodontal tissue by evaluating oxidative stress biomarkers in gingival crevicular fluid (GCF). Clinical periodontal parameters and blood serum lipid, GCF malondialdehyde (MDA), protein carbonyl (PC), and total antioxidant capacity (TAOC) levels were evaluated in six age and sex-matched groups (n = 15 each) of normolipidemic and hyperlipidemic individuals as follows: normolipidemic + periodontally healthy (H), normolipidemic + gingivitis (G), normolipidemic + chronic periodontitis (CP), hyperlipidemic + periodontally healthy (HH), hyperlipidemic + gingivitis (HG), and hyperlipidemic + CP (HCP). GCF MDA, and PC levels varied among groups, with patients with periodontitis having the highest MDA and PC levels [CP > G > H (p < 0.01) and HCP > HG > HH (p < 0.01)] and the lowest TAOC levels [CP < G < H (p < 0.01) and HCP < HG < HH (p < 0.01)]. Furthermore, paired comparisons showed MDA and PC levels to be higher and TAOC levels to be lower in HCP compared with NCP (p < 0.01). In patients with hyperlipidemia, GCF, MDA, and PC levels positively correlated with clinical assessments and serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL) levels and negatively correlated with serum high-density lipoprotein cholesterol (HDL) levels, whereas GCF TAOC levels negatively correlated with clinical assessments and serum TG, TC, and LDL levels, but positively correlated with serum HDL levels (p < 0.01). In normolipidemic patients, GCF, MDA, and PC levels positively correlated with clinical assessments and serum TG levels and negatively correlated with serum HDL levels, whereas GCF TAOC levels negatively correlated with clinical assessments and serum TG levels and positively correlated with serum HDL levels (p < 0.01). In conclusion, abnormal serum lipid subfractions could be considered a risk factor for enhancing oxidative stress in GCF in the presence of periodontal disease.
[Mh] MeSH terms primary: Chronic Periodontitis/blood
Gingival Crevicular Fluid/metabolism
Gingivitis/blood
Hyperlipidemias/blood
Oxidative Stress/physiology
[Mh] MeSH terms secundary: Adult
Analysis of Variance
Case-Control Studies
Cholesterol/blood
Chronic Periodontitis/etiology
Enzyme-Linked Immunosorbent Assay
Female
Gingivitis/etiology
Humans
Hyperlipidemias/complications
Male
Malondialdehyde/blood
Middle Aged
Protein Carbonylation/physiology
Reference Values
Statistics, Nonparametric
Triglycerides/blood
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Triglycerides); 4Y8F71G49Q (Malondialdehyde); 97C5T2UQ7J (Cholesterol)
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:D; IM
[Da] Date of entry for processing:171222
[St] Status:MEDLINE

  3 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28468786
[Au] Autor:Chang WT; Chang CL; Ho CH; Hong CS; Wang JJ; Chen ZC
[Ad] Address:Department of Cardiology, Chi Mei Medical Center, Tainan, Taiwan.
[Ti] Title:Long-Term Effects of Unprovoked Venous Thromboembolism on Mortality and Major Cardiovascular Events.
[So] Source:J Am Heart Assoc;6(5), 2017 May 03.
[Is] ISSN:2047-9980
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Patients with unprovoked venous thromboembolism (VTE) are at an increased risk of mortality, but whether their cardiovascular risks also increase remains to be determined. We aimed to investigate the factors associated with overall mortality and major adverse cardiovascular events in patients with unprovoked VTE. METHODS AND RESULTS: We identified 2154 patients newly diagnosed with unprovoked VTE from Taiwan's National Health Insurance Database between 2000 and 2013, excluding those with reversible etiologies, underlying cancer, or autoimmune diseases. These patients with VTE were compared with an age-, sex-, and cardiovascular risk-matched cohort of 4308 controls. The risk of mortality and major adverse cardiovascular events in patients with VTE was 2.23 (CI, 1.93-2.57; <0.0001) and 1.86 (CI, 1.65-2.09; <0.0001) times, respectively, higher than that of the conditions in controls. These events mostly occurred during the first year after the diagnosis of unprovoked VTE. Among patients with VTE, advanced age, male sex, and comorbid diabetes mellitus indicated a higher incidence of mortality and major adverse cardiovascular events. Conversely, comorbid hyperlipidemia attenuated these risks. CONCLUSIONS: This nation-wide cohort study revealed that patients with unprovoked VTE, particularly older males with diabetes mellitus, had an elevated risk of both mortality and cardiovascular events. Risk of mortality and major adverse cardiovascular events were highest within the first year after diagnosis and persisted during the 10 years of follow-up.
[Mh] MeSH terms primary: Venous Thromboembolism/mortality
[Mh] MeSH terms secundary: Adult
Age Factors
Aged
Comorbidity
Databases, Factual
Diabetes Mellitus/diagnosis
Diabetes Mellitus/mortality
Female
Humans
Hyperlipidemias/diagnosis
Hyperlipidemias/mortality
Incidence
Kaplan-Meier Estimate
Male
Middle Aged
Prognosis
Proportional Hazards Models
Protective Factors
Retrospective Studies
Risk Assessment
Risk Factors
Sex Factors
Taiwan/epidemiology
Time Factors
Venous Thromboembolism/diagnosis
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:170505
[St] Status:MEDLINE

  4 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29443736
[Au] Autor:Tang M; Xu JM; Song SS; Mei Q; Zhang LJ
[Ad] Address:Department of Gastroenterology, the First Hospital of Anhui Medical University.
[Ti] Title:What may cause fetus loss from acute pancreatitis in pregnancy: Analysis of 54 cases.
[So] Source:Medicine (Baltimore);97(7):e9755, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Acute pancreatitis in pregnancy (APIP) poses a serious threat to the mother and her fetus, and might lead to fetal loss including miscarriage and stillbirth in certain patients. We sought to identify possible factors that affect fetal distress and evaluated outcomes of patients with APIP.We retrospectively reviewed clinical records of 54 pregnant women with APIP, who were treated at 2 tertiary clinical centers over a 6-year period. Clinical characteristics including etiology and severity of APIP, fetal monitoring data, and maternofetal outcomes were analyzed.Etiology of APIP included acute biliary pancreatitis (ABP, n = 14), hyperlipidemic pancreatitis (HLP, n = 22), and other etiologies (n = 18). Severity was classified as mild acute pancreatitis (MAP, n = 23), moderately severe acute pancreatitis (MSAP, n = 24), and severe acute pancreatitis (SAP, n = 7). The incidence of preterm delivery, fetal distress, and fetal loss increased with the progression of severity of APIP (P < .05). The severity of HLP was significantly higher than that of ABP and APIP of other etiology (P < .01). HLP was more likely to lead to fetal distress than other APs (P < .01). Only 12 (22.2%) patients had fetal monitoring including non-stress test (NST); 1 case of SAP (14.3%) and 15 cases of MSAP (62.5%) were not transferred to intensive care unit for intensive monitoring.The incidence of fetal distress and fetal loss increased with worsening of APIP severity. HLP tends to result in worse fetal outcomes. The deficiencies of fetal state monitoring, lack of assessment, and management of pregnant women might increase the fetal loss in APIP.
[Mh] MeSH terms primary: Fetal Death/etiology
Pancreatitis/complications
Pregnancy Complications
[Mh] MeSH terms secundary: Acute Disease
Adult
Disease Progression
Female
Fetal Distress/epidemiology
Fetal Distress/etiology
Humans
Hyperlipidemias/complications
Incidence
Pancreatitis/epidemiology
Pancreatitis/etiology
Pregnancy
Pregnancy Complications/epidemiology
Pregnancy Complications/etiology
Premature Birth/epidemiology
Premature Birth/etiology
Retrospective Studies
Severity of Illness Index
Young Adult
[Pt] Publication type:EVALUATION STUDIES; JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009755

  5 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29254319
[Au] Autor:Musolino V; Gliozzi M; Carresi C; Maiuolo J; Mollace R; Bosco F; Scarano F; Scicchitano M; Maretta A; Palma E; Iannone M; Morittu VM; Gratteri S; Muscoli C; Fini M; Mollace V
[Ad] Address:Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Science, Magna Græcia University of Catanzaro, Catanzaro, Italy.
[Ti] Title:Lipid-lowering effect of bergamot polyphenolic fraction: role of pancreatic cholesterol ester hydrolase.
[So] Source:J Biol Regul Homeost Agents;31(4):1087-1093, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:Bergamot polyphenolic fraction (BPF) has been shown to positively modulate several mechanisms involved in metabolic syndrome, suggesting its use in therapy. In particular, it is able to induce a significant amelioration of serum lipid profile in hyperlipemic patients at different levels. The purpose of our study was to investigate the effect of BPF on cholesterol absorption physiologically mediated by pancreatic cholesterol ester hydrolase (pCEH). An in vitro activity assay was performed to study the effect of BPF on pCEH, whereas the rate of cholesterol absorption was evaluated through in vivo studies. In particular, male, Sprague-Dawley rats (200–225 g) were fed either normal chow or chow supplemented with 0.5% cholic acid, 5.5% peanut oil, and varying amounts of cholesterol (0 to 1.5%). BPF (10 mg/Kg) was daily administrated by means of a gastric gavage to animals fed with lipid supplemented diet for 4 weeks and, at the end of the study, plasma lipids and liver cholesteryl esters were measured in all experimental groups. Our results show that BPF was able to inhibit pCEH activity and this effect was confirmed, in vivo, via detection of lymphatic cholesteryl ester in rats fed with a cholesterol-rich diet. This evidence clarifies a further mechanism responsible for the hypolipemic properties of BPF previously observed in humans, confirming its beneficial effect in the therapy of hypercholesterolemia and in the treatment of metabolic syndrome.
[Mh] MeSH terms primary: Dietary Supplements
Hyperlipidemias/drug therapy
Hypolipidemic Agents/pharmacology
Plant Oils/pharmacology
Sterol Esterase/antagonists & inhibitors
[Mh] MeSH terms secundary: Animals
Cholesterol/administration & dosage
Cholesterol/blood
Cholesterol Esters/blood
Cholic Acid/administration & dosage
Cholic Acid/blood
Gastrointestinal Absorption/physiology
Humans
Hyperlipidemias/metabolism
Hyperlipidemias/pathology
Hypolipidemic Agents/metabolism
Liver/drug effects
Liver/metabolism
Male
Metabolic Syndrome/drug therapy
Metabolic Syndrome/metabolism
Metabolic Syndrome/pathology
Plant Oils/metabolism
Rats
Rats, Sprague-Dawley
Sterol Esterase/metabolism
Triglycerides/blood
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Cholesterol Esters); 0 (Hypolipidemic Agents); 0 (Plant Oils); 0 (Triglycerides); 39W1PKE3JI (bergamot oil); 97C5T2UQ7J (Cholesterol); EC 3.1.1.- (bile salt-stimulated lipase); EC 3.1.1.13 (Sterol Esterase); G1JO7801AE (Cholic Acid)
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:171220
[St] Status:MEDLINE

  6 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29384954
[Au] Autor:Li G; Qi G; Zhang B; Zhou B; Ma B; Jiang D; He Q; Ai C; Dai H; Li Y; Shi J
[Ad] Address:Department of Clinical Epidemiology, Institute of Cardiovascular Diseases.
[Ti] Title:The dose-response association between estimated glomerular filtration rate and prognosis of patients with ST-segment elevation myocardial infarction from rural areas of China's Liaoning province.
[So] Source:Medicine (Baltimore);96(52):e9508, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:We aimed to investigate the dose-response associations between chronic kidney disease (CKD), and short and long-term cardiovascular outcomes, to characterize these associations by drawing dose-response curves based on a Chinese rural ST-segment elevation myocardial infarction (STEMI) population.In all, 1067 patients with STEMI were consecutively enrolled from 12 secondary hospitals of China's Liaoning province (from June 2009 to June 2010 and January 2015 to December 2015). The follow-up was regularly performed by telephone. Patients were grouped by estimated glomerular filter rate (eGFR): normal, eGFR ≥90 mL/min/1.73 m; mild CKD, 60 to 90 mL/min/1.73 m; CKD, <60 mL/min/1.73 m. Adjusted logistic or Cox regression models were employed to compare short and long-term cardiovascular outcomes across different eGFR groups. Dose-response curves were plotted using restricted cubic spline functions.About 18.46% of the STEMI patients had CKD. Patients with CKD were more likely to suffer from other comorbidities, but less likely to receive evidence-based therapies. CKD was independently associated with in-hospital mortality and major adverse cardiac events (MACE) as compared with patients with normal renal function (for in-hospital mortality, adjusted odds ratio [OR] 2.39, 95% confidence interval [CI] 1.18-4.85, P = .02; for in-hospital MACE, adjusted OR 2.01, 95% CI 1.09-3.70, P < .01). Likewise, CKD was significantly associated with long-term mortality as well (CKD vs normal, adjusted hazard ratio 2.55, 95% CI 1.17-5.57, P = .02). The dose-response associations between eGFR, and short and long-term cardiovascular outcomes were found to be linear (all with P values for nonlinear associations >.05).CKD is an independent predictor of worse in-hospital and long-term clinical outcomes. The assessment of eGFR is essential to enable risk stratification, tailored therapy, and early and aggressive management.
[Mh] MeSH terms primary: Glomerular Filtration Rate
Renal Insufficiency, Chronic/epidemiology
ST Elevation Myocardial Infarction/epidemiology
[Mh] MeSH terms secundary: Adult
Age Factors
Aged
Aged, 80 and over
Biomarkers
Cardiovascular Diseases/epidemiology
China/epidemiology
Comorbidity
Drosophila Proteins
Female
Hospital Mortality
Humans
Hyperlipidemias/epidemiology
Logistic Models
Male
Membrane Proteins
Middle Aged
Prognosis
Proportional Hazards Models
Renal Insufficiency, Chronic/pathology
Rural Population
ST Elevation Myocardial Infarction/mortality
Severity of Illness Index
[Pt] Publication type:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Name of substance:0 (Biomarkers); 0 (Drosophila Proteins); 0 (Membrane Proteins); 0 (expanded protein, Drosophila)
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009508

  7 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29381966
[Au] Autor:Liu MX; Wen XY; Leung YK; Zheng YJ; Jin MS; Jin QL; Niu JQ
[Ad] Address:Department of Hepatology, The First Hospital of Jilin University.
[Ti] Title:Hemolytic anemia in alcoholic liver disease: Zieve syndrome: A case report and literature review.
[So] Source:Medicine (Baltimore);96(47):e8742, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Zieve syndrome, a rarely reported disease resulting from alcohol abuse, consists of a triad of symptoms: hemolytic anemia, cholestatic jaundice, and transient hyperlipidemia. It is largely under-recognized and under-reported, possibly because of unawareness of the condition by physicians. Here, we report a case of Zieve syndrome managed at the Jilin University First Bethune Hospital. PATIENT CONCERNS: A 30-year-old Chinese woman presented with a 4-month history of fatigue, yellowish discoloration of the eyes, and tea-colored urine. She had been a heavy drinker for 2 years prior to onset of the disease with an average daily alcohol intake of 60 g/d and more than 80 g/d for the previous 6 months. DIAGNOSIS: The diagnosis of Zieve syndrome was confirmed based on hemolysis and cholestatic jaundice secondary to alcoholic liver disease and heavy drinking. Bone marrow biopsy and liver biopsy both supported the diagnosis. INTERVENTIONS: We treated her with abstinence from alcohol and supportive therapy. OUTCOMES: The patient was discharged 14 days after admission with an improvement in symptoms, which continued to subside during the 2-month follow-up period. LESSONS: Doctors confronted with hemolysis in a patient with alcoholic liver disease should be aware of the under-reported Zieve syndrome. Recognition of this syndrome could help doctors avoid unnecessary invasive procedures and emphasize the importance of alcohol abstinence as the mainstay of management. Glucocorticoids may not be useful in treating hemolytic anemia in Zieve syndrome.
[Mh] MeSH terms primary: Anemia, Hemolytic/complications
Liver Diseases, Alcoholic/complications
[Mh] MeSH terms secundary: Adult
Female
Humans
Hyperlipidemias/etiology
Jaundice/etiology
Syndrome
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008742

  8 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28464819
[Au] Autor:Imran M; Arshad MS; Butt MS; Kwon JH; Arshad MU; Sultan MT
[Ad] Address:Department of Diet and Nutritional Sciences, Imperial College of Business Studies, Lahore, Pakistan.
[Ti] Title:Mangiferin: a natural miracle bioactive compound against lifestyle related disorders.
[So] Source:Lipids Health Dis;16(1):84, 2017 May 02.
[Is] ISSN:1476-511X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The current review article is an attempt to explain the therapeutic potential of mangiferin, a bioactive compound of the mango, against lifestyle-related disorders. Mangiferin (2-ß-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one) can be isolated from higher plants as well as the mango fruit and their byproducts (i.e. peel, seed, and kernel). It possesses several health endorsing properties such as antioxidant, antimicrobial, antidiabetic, antiallergic, anticancer, hypocholesterolemic, and immunomodulatory. It suppresses the activation of peroxisome proliferator activated receptor isoforms by changing the transcription process. Mangiferin protects against different human cancers, including lung, colon, breast, and neuronal cancers, through the suppression of tumor necrosis factor α expression, inducible nitric oxide synthase potential, and proliferation and induction of apoptosis. It also protects against neural and breast cancers by suppressing the expression of matrix metalloproteinase (MMP)-9 and MMP-7 and inhibiting enzymatic activity, metastatic potential, and activation of the ß-catenin pathway. It has the capacity to block lipid peroxidation, in order to provide a shielding effect against physiological threats. Additionally, mangiferin enhances the capacity of the monocyte-macrophage system and possesses antibacterial activity against gram-positive and gram-negative bacteria. This review summarizes the literature pertaining to mangiferin and its associated health claims.
[Mh] MeSH terms primary: Anti-Inflammatory Agents/therapeutic use
Antineoplastic Agents, Phytogenic/therapeutic use
Antioxidants/therapeutic use
Hypoglycemic Agents/therapeutic use
Nootropic Agents/therapeutic use
Xanthones/therapeutic use
[Mh] MeSH terms secundary: Anti-Inflammatory Agents/chemistry
Anti-Inflammatory Agents/isolation & purification
Antineoplastic Agents, Phytogenic/chemistry
Antineoplastic Agents, Phytogenic/isolation & purification
Antioxidants/chemistry
Antioxidants/isolation & purification
Cardiovascular Diseases/drug therapy
Cardiovascular Diseases/pathology
Cognitive Dysfunction/drug therapy
Cognitive Dysfunction/pathology
Diabetes Mellitus, Type 2/drug therapy
Diabetes Mellitus, Type 2/pathology
Humans
Hyperlipidemias/drug therapy
Hyperlipidemias/pathology
Hypoglycemic Agents/chemistry
Hypoglycemic Agents/isolation & purification
Mangifera/chemistry
Neoplasms/drug therapy
Neoplasms/pathology
Neuralgia/drug therapy
Neuralgia/pathology
Nootropic Agents/chemistry
Nootropic Agents/isolation & purification
Oxidative Stress/drug effects
Xanthones/chemistry
Xanthones/isolation & purification
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Anti-Inflammatory Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Antioxidants); 0 (Hypoglycemic Agents); 0 (Nootropic Agents); 0 (Xanthones); 1M84LD0UMD (mangiferin)
[Em] Entry month:1802
[Cu] Class update date: 180219
[Lr] Last revision date:180219
[Js] Journal subset:IM
[Da] Date of entry for processing:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12944-017-0449-y

  9 / 25489 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28464894
[Au] Autor:Zhao MJ; Wang SS; Jiang Y; Wang Y; Shen H; Xu P; Xiang H; Xiao H
[Ad] Address:Nanjing Medical University, Affiliated Nanjing Brain Hospital, No. 264 Guangzhou Road, Nanjing, Jiangsu, 210029, People's Republic of China.
[Ti] Title:Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism.
[So] Source:Lipids Health Dis;16(1):85, 2017 May 02.
[Is] ISSN:1476-511X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: The novel compound XH601 is a synthesized derivative of formononetin. The present study was to investigate the hypolipidemia effect and potential mechanism of XH601. METHODS: Male Golden Syrian hamsters were induced by high-fat diet (HFD) for eight weeks and the hyperlipidemic model was established successfully. After XH601 treatment, serum and hepatic biochemistry parameters of hamsters were detected and the effect of XH601 on adipose tissue was also analyzed. Furthermore, 3 T3-L1 cell differentiation by Oil-Red-O staining was observed and the mRNA and protein expression of peroxisome proliferator-activated receptors (PPARs) were measured by qRT-PCR and Western-blot in mature adipocytes. RESULTS: The in vivo results suggest that XH601 significantly decreased the adipose weight and levels of serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL-C), apolipoprotein B (Apo-B), apolipoprotein E (Apo-E), while increased serum high-density lipoprotein (HDL-C). The in vitro results implied that XH601 up-regulated the mRNA and protein expression of both PPARα and PPARß/δ in a dose-dependent manner. CONCLUSIONS: The study suggests that XH601 exhibited strong ability to improve the dyslipidemia in hamsters fed with high-fat diet. The potential mechanism of XH601 was associated with the up-regulation of PPARα and PPARß/δ mRNA and protein expression.
[Mh] MeSH terms primary: Hyperlipidemias/drug therapy
Hypolipidemic Agents/pharmacology
Isoflavones/pharmacology
PPAR alpha/agonists
PPAR delta/agonists
PPAR-beta/agonists
[Mh] MeSH terms secundary: 3T3-L1 Cells
Adipose Tissue/drug effects
Adipose Tissue/metabolism
Adipose Tissue/pathology
Animals
Apolipoproteins B/blood
Apolipoproteins E/blood
Cell Differentiation
Cholesterol, HDL/blood
Cholesterol, LDL/blood
Cricetinae
Diet, High-Fat/adverse effects
Gene Expression Regulation
Hyperlipidemias/etiology
Hyperlipidemias/metabolism
Hyperlipidemias/pathology
Male
Mesocricetus
Mice
PPAR alpha/genetics
PPAR alpha/metabolism
PPAR delta/genetics
PPAR delta/metabolism
PPAR-beta/genetics
PPAR-beta/metabolism
RNA, Messenger/agonists
RNA, Messenger/genetics
RNA, Messenger/metabolism
Triglycerides/blood
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Apolipoproteins B); 0 (Apolipoproteins E); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (Hypolipidemic Agents); 0 (Isoflavones); 0 (PPAR alpha); 0 (PPAR delta); 0 (PPAR-beta); 0 (RNA, Messenger); 0 (Triglycerides); 295DQC67BJ (formononetin)
[Em] Entry month:1802
[Cu] Class update date: 180219
[Lr] Last revision date:180219
[Js] Journal subset:IM
[Da] Date of entry for processing:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12944-017-0472-z

  10 / 25489 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29422049
[Au] Autor:Etxeberria A; Alcorta I; Pérez I; Emparanza JI; Ruiz de Velasco E; Iglesias MT; Rotaeche R
[Ad] Address:Donostialdea Integrated Healthcare Organization, Osakidetza-Basque Health Service, Biodonostia Health Research Institute, Hernani, Spain. arritxuetxe@gmail.com.
[Ti] Title:Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain.
[So] Source:BMC Health Serv Res;18(1):93, 2018 02 08.
[Is] ISSN:1472-6963
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: The implementation of evidence-based clinical practice guidelines (CPG) can improve patients care. To date, the impact of implementation strategies has not been evaluated in our context. This study is aimed to evaluate the effectiveness of a multifaceted tailored intervention targeting clinician education for the implementation of three cardiovascular risk-related CPGs (type 2 diabetes, hypertension and dyslipidemia) in primary care at the Basque Health Service compared with usual implementation. METHODS: We conducted a cluster randomized controlled trial in two urban districts with 43 primary care units (PCU). Data from all patients diagnosed with diabetes, hypertension and all those eligible for coronary risk (CR) assessment were included. In the control group, guidelines were introduced in the usual way (by email, intranet and clinical meetings). In the intervention group, the implementation also included a specific website and workshops. Primary endpoints were annual HbA1c testing (diabetes), annual general laboratory testing (hypertension) and annual CR assessment (dyslipidemia). Secondary endpoints were process, prescription and clinical endpoints related with guideline recommendations. Analysis was performed at a PCU level weighted by cluster size. RESULTS: Significant differences between groups were observed in primary outcomes in the dyslipidemia CPG: increased CR assessment for both women and men (weighted mean difference, WMD, 13.58 and 12.91%). No significant differences were observed in diabetes and hypertension CPGs primary outcomes. Regarding secondary endpoints, annual CR assessment was significantly higher in both diabetic and hypertensive patients in the intervention group (WMD 28.16 and 27.55%). Rates of CR assessment before starting new statin treatments also increased (WMD 23.09%), resulting in a lower rate of statin prescribing in low risk women. Diuretic prescribing was higher in the intervention group (WMD 20.59%). Clinical outcomes (HbA1c and blood pressure control) did not differ between groups. CONCLUSIONS: The multifaceted implementation proved to be effective to increase the CR assessment and to improve prescription, but ineffective to improve diabetes and hypertension related outcomes. In order to obtain real improvements when cardiovascular issues are tackled, perhaps other or additional interventions need to be implemented besides education of professionals. TRIAL REGISTRATION: Current Controlled Trials, ISRCTN 88876909 (retrospectively registered on January 13, 2009).
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1802
[Cu] Class update date: 180218
[Lr] Last revision date:180218
[St] Status:In-Process
[do] DOI:10.1186/s12913-018-2863-x


page 1 of 2549 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information